Eric M Parise1, Lyonna F Parise1, Omar K Sial2, Astrid M Cardona-Acosta3, Trevonn M Gyles1, Barbara Juarez4, Dipesh Chaudhury5, Ming-Hu Han6, Eric J Nestler7, Carlos A Bolaños-Guzmán8. 1. Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Department of Psychological and Brain Sciences, Texas A&M University, College Station, Texas; Institute for Neuroscience, Texas A&M University, College Station, Texas. 3. Department of Psychological and Brain Sciences, Texas A&M University, College Station, Texas. 4. Department of Pharmacological Sciences, Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Pharmacology, University of Washington, Seattle, Washington. 5. Department of Pharmacological Sciences, Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Science, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates. 6. Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Center for Affective Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Pharmacological Sciences, Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, New York. 7. Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: eric.nestler@mssm.edu. 8. Department of Psychological and Brain Sciences, Texas A&M University, College Station, Texas; Institute for Neuroscience, Texas A&M University, College Station, Texas. Electronic address: bolanos@tamu.edu.
Abstract
BACKGROUND: Major depressive disorder is prevalent in children and adolescents and is associated with a high degree of morbidity throughout life, with potentially devastating personal consequences and public health impact. The efficacy of ketamine (KET) as an antidepressant has been demonstrated in adolescent rodents; however, the neurobiological mechanisms underlying these effects are unknown. Recent evidence showed that KET reverses stress-induced (i.e., depressive-like) deficits within major mesocorticolimbic regions, such as the prefrontal cortex, nucleus accumbens (NAc), and hippocampus, in adult rodents. However, little is known about KET's effect in the ventral tegmental area (VTA), which provides the majority of dopaminergic input to these brain regions. METHODS: We characterized behavioral, biochemical, and electrophysiological effects produced by KET treatment in C57BL/6J male mice during adolescence (n = 7-10 per condition) within the VTA and its major projection regions, namely, the NAc and prefrontal cortex. Subsequently, molecular targets within the VTA-NAc projection were identified for viral gene transfer manipulations to recapitulate the effects of stress or KET treatment. RESULTS: Repeated KET treatment produced a robust proresilient response to chronic social defeat stress. This effect was largely driven by Akt signaling activity within the VTA and NAc, and it could be blocked or recapitulated through direct Akt-viral-mediated manipulation. Additionally, we found that the KET-induced resilient phenotype is dependent on VTA-NAc, but not VTA-prefrontal cortex, pathway activity. CONCLUSIONS: These findings indicate that KET exposure during adolescence produces a proresilient phenotype mediated by changes in Akt intracellular signaling and altered neuronal activity within the VTA-NAc pathway.
BACKGROUND: Major depressive disorder is prevalent in children and adolescents and is associated with a high degree of morbidity throughout life, with potentially devastating personal consequences and public health impact. The efficacy of ketamine (KET) as an antidepressant has been demonstrated in adolescent rodents; however, the neurobiological mechanisms underlying these effects are unknown. Recent evidence showed that KET reverses stress-induced (i.e., depressive-like) deficits within major mesocorticolimbic regions, such as the prefrontal cortex, nucleus accumbens (NAc), and hippocampus, in adult rodents. However, little is known about KET's effect in the ventral tegmental area (VTA), which provides the majority of dopaminergic input to these brain regions. METHODS: We characterized behavioral, biochemical, and electrophysiological effects produced by KET treatment in C57BL/6J male mice during adolescence (n = 7-10 per condition) within the VTA and its major projection regions, namely, the NAc and prefrontal cortex. Subsequently, molecular targets within the VTA-NAc projection were identified for viral gene transfer manipulations to recapitulate the effects of stress or KET treatment. RESULTS: Repeated KET treatment produced a robust proresilient response to chronic social defeat stress. This effect was largely driven by Akt signaling activity within the VTA and NAc, and it could be blocked or recapitulated through direct Akt-viral-mediated manipulation. Additionally, we found that the KET-induced resilient phenotype is dependent on VTA-NAc, but not VTA-prefrontal cortex, pathway activity. CONCLUSIONS: These findings indicate that KET exposure during adolescence produces a proresilient phenotype mediated by changes in Akt intracellular signaling and altered neuronal activity within the VTA-NAc pathway.
Authors: Demitri F Papolos; Martin H Teicher; Gianni L Faedda; Patricia Murphy; Steven Mattis Journal: J Affect Disord Date: 2012-11-30 Impact factor: 4.839
Authors: J M Witkin; J A Monn; D D Schoepp; X Li; C Overshiner; S N Mitchell; G Carter; B Johnson; K Rasmussen; L M Rorick-Kehn Journal: J Pharmacol Exp Ther Date: 2016-05-12 Impact factor: 4.030
Authors: Christopher J Kratochvil; Benedetto Vitiello; John Walkup; Graham Emslie; Bruce D Waslick; Elizabeth B Weller; William J Burke; John S March Journal: J Child Adolesc Psychopharmacol Date: 2006 Feb-Apr Impact factor: 2.576
Authors: Dipesh Chaudhury; Jessica J Walsh; Allyson K Friedman; Barbara Juarez; Stacy M Ku; Ja Wook Koo; Deveroux Ferguson; Hsing-Chen Tsai; Lisa Pomeranz; Daniel J Christoffel; Alexander R Nectow; Mats Ekstrand; Ana Domingos; Michelle S Mazei-Robison; Ezekiell Mouzon; Mary Kay Lobo; Rachael L Neve; Jeffrey M Friedman; Scott J Russo; Karl Deisseroth; Eric J Nestler; Ming-Hu Han Journal: Nature Date: 2012-12-12 Impact factor: 49.962
Authors: Chadi G Abdallah; Lynnette A Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Mohamed Sherif; Kyung-Heup Ahn; Deepak Cyril D'Souza; Richard Formica; Steven M Southwick; Ronald S Duman; Gerard Sanacora; John H Krystal Journal: Neuropsychopharmacology Date: 2020-02-24 Impact factor: 7.853
Authors: Marco Pagliusi; Daniela Franco; Shannon Cole; Gessynger Morais-Silva; Ramesh Chandra; Megan E Fox; Sergio D Iñiguez; Cesar R Sartori; Mary Kay Lobo Journal: Front Psychiatry Date: 2022-06-02 Impact factor: 5.435
Authors: Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678
Authors: Alessia Mastrodonato; Ina Pavlova; Noelle Kee; Josephine C McGowan; J John Mann; Christine A Denny Journal: Front Neurosci Date: 2022-04-21 Impact factor: 4.677
Authors: Evgeniy Svirin; Ekaterina Veniaminova; João Pedro Costa-Nunes; Anna Gorlova; Aleksei Umriukhin; Allan V Kalueff; Andrey Proshin; Daniel C Anthony; Andrey Nedorubov; Anna Chung Kwan Tse; Susanne Walitza; Lee Wei Lim; Klaus-Peter Lesch; Tatyana Strekalova Journal: Cells Date: 2022-03-18 Impact factor: 6.600